

## Supplementary Information

**Table S1.** Correlation of *RhoA* and *Wnt-5a* mRNA expression with tumorigenesis and aggressiveness of ovarian carcinoma.

Clinicopathological features	<i>n</i>	<i>RhoA</i> mRNA expression/GAPDH	<i>Wnt-5a</i> mRNA expression/GAPDH
<b>Pathological classification</b>			
Serous adenocarcinoma	46	0.003032 ± 0.003243	0.000747 ± 0.000736
Miscellaneous subtypes	14	0.002432 ± 0.003582	0.001261 ± 0.001421
<b>FIGO staging</b>			
I–II	31	0.002067 ± 0.002787	0.000749 ± 0.000856
III–IV	29	0.003773 ± 0.003621 *	0.001144 ± 0.000985 *
<b>Differentiation</b>			
Well	15	0.001717 ± 0.003162	0.000516 ± 0.000575
Moderate	28	0.002559 ± 0.002976	0.000733 ± 0.000874
Poor	17	0.004476 ± 0.003522 **	0.001396 ± 0.001147 **

\* Compared with International Federation of Gynecology and Obstetrics (FIGO) stage I/II ( $p = 0.0445$ ;  $p = 0.0279$ ); \*\* Compared with moderately differentiated and well differentiated ( $p = 0.0182$ ;  $p = 0.0057$ ).

**Table S2.** Correlation of *RhoA* and *Wnt-5a* protein expression with tumorigenesis and aggressiveness of ovarian carcinoma.

Clinicopathological features	<i>n</i>	<i>RhoA</i> protein expression/GAPDH	<i>Wnt-5a</i> protein expression/GAPGH
<b>Pathological classification</b>			
Serous adenocarcinoma	56	1.684880 ± 1.400929	0.563563 ± 0.489970
Miscellaneous subtypes	16	1.285997 ± 0.589267	0.452062 ± 0.181456
<b>FIGO staging</b>			
I–II	32	1.251530 ± 0.698392	0.421421 ± 0.252762
III–IV	40	1.872007 ± 1.545606 *	0.632676 ± 0.532978 *
<b>Differentiation</b>			
Well	20	1.259664 ± 0.617077	0.452474 ± 0.202293
Moderate	31	1.396119 ± 0.785278	0.441835 ± 0.268450
Poor	21	2.212203 ± 1.973854 **	0.764103 ± 0.685803 **

\* Compared with International Federation of Gynecology and Obstetrics (FIGO) stage I/II ( $p = 0.0390$ ;  $p = 0.0429$ ); \*\* Compared with moderately differentiated and well differentiated ( $p = 0.007514$ ;  $p = 0.004691$ ).

**Table S3.** RT-PCR primers.

<i>Gene</i>	Primer sequence	Target sequence	AT (°C)	Product size (bp)	Extension time (s)
<i>RhoA</i>	F: 5'-ACTCGGATTCGTTGCC-3'	NM-001664	60	276	34
	R: 5'-TTGGGACAGAAATGCTTGA-3'	585-860			
<i>Wnt-5a</i>	F: 5'-GCGAAGACAGGCATCAAA-3'	NM-003392	60	295	34
	R: 5'-CCTTGGCAAAGCGGTAG-3'	946-1240			
<i>P70S6k</i>	F: 5'-TAAAGCATCCCTTCATCG-3'	NM_003161	60	139	34
	R: 5'-CAGGCAGTGTCTCCATAA-3'	552-690			
<i>PI3K</i>	F: 5'-CACCGCATTGTGTCGT-3'	NM_001242466	60	225	34
	R: 5'-CTCCACTTCTACGC-3'	4016-4240			
<i>Akt</i>	F: 5'-GGGACAGAGGAGCAAGGT-3'	NM_005163	60	208	34
	R: 5'-CGACAGCGGAAAGGTAA-3'	2656-2863			
<i>Bcl/xL</i>	F: 5'-TTCCCAGAAAGGATACAGC-3'	Z23115	60	92	34
	R: 5'-GGGTCTCCATCTCCGATT-3'	185-276			
Survivin	F: 5'-CTTGGCCCAGTGTTTCTT-3'	DQ227257	60	124	34
	R: 5'-GCTTCCAGTCCCTCCCT-3'	159-282			
<i>VEGF</i>	F: 5'-AGGAGGAGGGCAGAATC-3'	NM_001171630	60	258	34
	R: 5'-ATGTGCTGGCCTTGGT-3'	1131-1388			
<i>GAPDH</i>	F: 5'-CAATGACCCCTTCATTGACC-3'	NM_002046.3	60	135	34
	R: 5'-TGGAAGATGGTGATGGGATT-3'	201-335			

AT = annealing temperature.

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).